Clinical medication response under new major infectious disease: off-label use and compassionate use
10.12206/j.issn.1006-0111.202003035
- VernacularTitle:新发重大传染病的临床治疗药物应对：超说明书用药与同情用药
- Author:
Zhuman LI
1
;
Zhijun GUO
1
;
Feng XU
1
Author Information
1. Fengxian Hospital, Southern Medical University, Shanghai 201400, China.
- Keywords:
medication response;
new major infectious disease;
off-label use;
compassionate use
- From:
Journal of Pharmaceutical Practice
2020;38(3):207-210
- CountryChina
- Language:Chinese
-
Abstract:
At present, there are no specific targeted drugs for the treatment of pneumonia (COVID-19) caused by the novel coronavirus (SARS-CoV-2). Interferon, lopinavir/ritonavir, ribavirin, chloroquine phosphate were chosen as off-label use, and remdesivir was chosen as compassionate use. This paper reviewed the behavior of the two medication response to the new major infectious disease.
